Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer

被引：2
|
作者：
Talwar, Ashna
Deshmukh, Ashish
Trivedi, Meghana
Aparasu, Rajender R.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4364
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4364
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
    Johnston, Stephen
    Toi, Masakazu
    O'Shaughnessy, Joyce
    Rastogi, Priya
    Campone, Mario
    Neven, Patrick
    Huang, Chiun Sheng
    Huober, Jens
    Jaliffe, Georgina Garnica
    Cicin, Irfan
    Tolaney, Sara
    Goetz, Matthew P.
    Rugo, Hope
    Senkus, Elzbieta
    Testa, Laura
    Del Mastro, Lucia
    Shimizu, Chikako
    Wei, Ran
    Shahir, Ashwin
    Munoz, Maria
    Antonio, Belen San
    Andre, Valerie
    Harbeck, Nadia
    Martin, Miguel
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer
    Valerio, Maria Rosaria
    Martorana, Federica
    Sano, Maria Vita
    Sambataro, Daniela
    Motta, Gianmarco
    Motta, Lucia
    Pavone, Giuliana
    Gebbia, Vittorio
    Scandurra, Giuseppa
    BIOMEDICINES, 2025, 13 (03)
  • [23] Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
    Turner, Nicholas
    Reis-Filho, Jorge
    Goetz, Matthew
    Desmedt, Christine
    Chandarlapaty, Sarat
    Sasano, Hironobu
    Arteaga, Carlos
    Loi, Sherene
    Graff, Stephanie
    Liu, Deli
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Rubenstein, Cynthia Sandoval
    Won, Helen
    Litchfield, Lacey M.
    Munoz, Maria
    Johnston, Stephen
    CANCER RESEARCH, 2024, 84 (09)
  • [24] Real-world study on HR+, HER2-, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns
    Pivot, X.
    Chartier, F.
    Chouaki, N.
    Brown, J.
    Williams, R.
    Rider, A.
    BREAST, 2021, 56 : S37 - S38
  • [25] Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial
    Rubenstein, C. S.
    Turner, N.
    Reis-Filho, J. S.
    Goetz, M. P.
    Desmedt, C.
    Chandarlapaty, S.
    Sasano, H.
    Arteaga, C. L.
    Loi, S.
    Graff, S. L.
    Liu, D.
    Rodrik-Outmezguine, V.
    Sireci, A.
    Won, H.
    Litchfield, L. M.
    Munoz, M.
    Johnston, S.
    BREAST, 2025, 80
  • [26] Abemaciclib combined with endocrine therapy for the adjuvant treatment of high-risk early breast cancer
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Mazakazu
    Martin, Miguel
    Shao, Zhimin
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Cortes, Javier
    Neven, Patrick
    Boyle, Frances
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 112 - 113
  • [27] Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis
    Wolowacz, Sorrel E.
    Cameron, David A.
    Tate, Helen C.
    Bagust, Adrian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 925 - 933
  • [28] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E. P.
    Huang, C.
    Senkus-Konefka, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R. J.
    Andre, V.
    Munoz, M.
    Antonio, B. San
    Shahir, A.
    Jimenez, M. Martin
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
  • [29] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
    Andre, V.
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E.
    Huang, C. -s.
    Senkus, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R.
    Munoz, M.
    Antonio, B. S.
    Shahir, A.
    Martin, M.
    Johnston, S.
    BREAST, 2025, 80
  • [30] Cost-effectiveness of adjuvant chemotherapy in node-positive breast cancer
    Orsi, Cecilia
    Caccese, Erminia
    Cecchi, Michele
    Messori, Andrea
    Tendi, Enrico
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 453 - 454
12345